Plasma levels of nm23-H1 in normal control and hematologic malignancy
| Diagnosis . | No. of patients . | Plasma level of nm23-H1 (mean ± SD) . | P value* . |
|---|---|---|---|
| Normal control | 21 | 6.1 ± 4.1 | — |
| AML | 102 | 61.8 ± 34.6 | .0001 |
| M0 | 3 | 60.9 ± 17.7 | .0065 |
| M1 | 18 | 62.6 ± 29.2 | .0001 |
| M2 | 25 | 58.4 ± 35.8 | .0001 |
| M3 | 14 | 47.0 ± 30.6 | .0002 |
| M4 | 17 | 57.1 ± 35.3 | .0001 |
| M5 | 16 | 72.4 ± 31.3 | .0001 |
| M6 | 6 | 110.0 ± 33.6 | .0006 |
| M7 | 3 | 28.6 ± 0.5 | .0001 |
| ALL | 6 | 65.7 ± 40.2 | .0003 |
| CML-CP | 13 | 26.9 ± 14.6 | .0001 |
| CML-BC | 8 | 99.0 ± 20.8 | .0001 |
| MDS | 12 | 34.9 ± 12.9 | .0001 |
| MDS-overt leukemia | 6 | 104.7 ± 34.3 | .0003 |
| MM | 21 | 34.5 ± 19.6 | .0001 |
| CLL | 4 | 18.9 ± 4.1 | .0020 |
| Diagnosis . | No. of patients . | Plasma level of nm23-H1 (mean ± SD) . | P value* . |
|---|---|---|---|
| Normal control | 21 | 6.1 ± 4.1 | — |
| AML | 102 | 61.8 ± 34.6 | .0001 |
| M0 | 3 | 60.9 ± 17.7 | .0065 |
| M1 | 18 | 62.6 ± 29.2 | .0001 |
| M2 | 25 | 58.4 ± 35.8 | .0001 |
| M3 | 14 | 47.0 ± 30.6 | .0002 |
| M4 | 17 | 57.1 ± 35.3 | .0001 |
| M5 | 16 | 72.4 ± 31.3 | .0001 |
| M6 | 6 | 110.0 ± 33.6 | .0006 |
| M7 | 3 | 28.6 ± 0.5 | .0001 |
| ALL | 6 | 65.7 ± 40.2 | .0003 |
| CML-CP | 13 | 26.9 ± 14.6 | .0001 |
| CML-BC | 8 | 99.0 ± 20.8 | .0001 |
| MDS | 12 | 34.9 ± 12.9 | .0001 |
| MDS-overt leukemia | 6 | 104.7 ± 34.3 | .0003 |
| MM | 21 | 34.5 ± 19.6 | .0001 |
| CLL | 4 | 18.9 ± 4.1 | .0020 |
Mann-Whitney U test (versus control). AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML-CP, chronic myelogenous leukemia-chronic phase; CML-BC, chronic myelogenous leukemia-blast crisis; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia.